A Phase 1 clinical trial referencing insulin degludec began recruiting as of September 15, 2026. The study, registered as NCT07630233, is titled "A Phase I Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Subcutaneous UBT38006 Injection in Healthy Adult Males."
According to the registry listing, the trial is in Phase 1 and is currently recruiting participants. The stated focus is on evaluating safety, tolerability, pharmacokinetics, and pharmacodynamics following a single subcutaneous injection of UBT38006 in healthy adult male volunteers.
No results have been posted for this trial at this time. The current status reflects an active recruitment phase rather than any reported outcomes. As with all Phase 1 studies, this stage is focused on initial human data collection rather than efficacy conclusions.
Readers interested in additional information can consult the compound overview page for further context on insulin degludec.